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The 5th Scientific Conference of the International Pemphigus and Pemphigoid
Foundation (IPPF), “Pemphigus and Pemphigoid: A New Era of Clinical and Translational
Science” was held in Orlando, Florida, on May 15–16, 2018. Scientific sessions covered
recent, ongoing, and future clinical trials in pemphigus and bullous pemphigoid, disease
activity and quality of life instruments, and the IPPF Natural History Study. Furthermore,
the meeting provided an opportunity to hear firsthand from patients, investigators, and
industry about their experience enrolling for clinical trials.
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INTRODUCTION
Following successful meetings in Bethesda, Maryland, USA in 2001, 2005, and 2010, and Lübeck,
Germany in 2017, the 5th International Pemphigus and Pemphigoid Foundation (IPPF) Scientific
Conference was the first meeting to focus on clinical trials in pemphigus and pemphigoid and
their methodologies. The meeting was organized by Drs. Aimee S. Payne, Victoria P. Werth,
Russell P. Hall III, and IPPF Director Marc L. Yale and brought together over 175 researchers,
clinicians, industry representatives, and patients representing 13 different countries to discuss the
latest scientific and clinical data from technologies advancing to clinical trials in pemphigus and
pemphigoid.
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WHAT’S NEW IN PEMPHIGUS AND
PEMPHIGOID CLINICAL TRIALS?
The first session of the meeting focused on results of ongoing
and recently completed clinical trials in pemphigus, moderated
by Drs. John Stanley (University of Pennsylvania, Philadelphia,
PA, USA) and Ron Feldman (Emory University, Atlanta, GA,
USA), as well as pemphigoid, moderated by Drs. David Woodley
(University of Southern California, Los Angeles, CA, USA) and
Enno Schmidt (University of Lübeck, Lübeck, Germany).
Pemphigus
B cells are major effector cells in autoimmunity, both
through autoantibody production as well as cellular tolerance
mechanisms. Dr. Philippe Musette (Rouen University Hospital,
Rouen, France) spoke about major advances being made
in refractory pemphigus patients by using B cell depleting
therapies, in particular the anti-CD20 monoclonal antibody
rituximab. A recent clinical trial (NCT00784589) supports
rituximab usage as a first line therapy in pemphigus patients
(1). Additionally, B cell depletion in patients represents an
opportunity to better understand pemphigus pathophysiology
and human B cell biology. Dr. Musette reported that rituximab
induces a prolonged and continuous repopulation of naive B
cells with a new repertoire after the initial B cell depletion,
whereas the reappearance of memory B cells is markedly delayed
(2). IL-10-producing regulatory B cells are also expanded
and are capable of downregulating inflammation, making
them potentially important for maintenance of tolerance. This
delay of B cell maturation is associated with a blockage of the
auto-reactive IgM to IgG class switching process. Thus, B cell
depletion induces a two-step mechanism of immunosuppression
in pemphigus by eliminating the autoreactive B cells involved
in the production of pathogenic IgG+ autoantibodies and by
promoting the appearance of regulatory B cells that can maintain
long term immune tolerance.
Inhibition of Bruton’s tyrosine kinase (BTK), a protein
essential for B cell development, is an appealing therapeutic
strategy for pemphigus based on the dual mechanism of
action to block autoantibody production as well as to quickly
dampen inflammation by inhibiting B cell activation. Dr. Dedee
Murrell (University of New South Wales, Sydney, Australia)
reported on an open label study of the oral BTK inhibitor,
PRN1008 (NCT02704429), which was previously tested in
healthy volunteers (3). In the current study, safety and efficacy
was demonstrated in 21 pemphigus patients with mild to
moderate disease (Pemphigus Disease Area Index score of 8–
39), with a disease duration between 0 and 20 years. The
primary endpoint of control of disease activity after 4 weeks
treatment with PRN1008 was met in 61% of patients, who
were concomitantly using a daily prednisone dose between 0
and 30mg. PRN1008 will shortly commence a large, global,
placebo-controlled, randomized phase 3 study in patients with
pemphigus.
Inhibition of the neonatal Fc receptor (FcRn) can promote
protection from autoimmunity by reducing serum antibody
levels and blocking pro-inflammatory immune pathways.
Recently, a humanized IgG4monoclonal antibody was developed
that specifically inhibits FcRn function (SYNT001) (4). This
antibody has been evaluated in a phase 1b open label safety,
tolerability, and activity study to treat subjects with pemphigus
(NCT03075904). Dr. Russell Hall (Duke University, Durham,
NC, USA) presented results of the phase 1b study showing that
infusion of SYNT001 in human subjects resulted in a rapid
lowering of circulating levels of IgG and was safe and well-
tolerated. Subjects were found to have a mean total IgG reduction
of 56% by Day 30, and 5 of 7 subjects showed reduction in disease
activity by day 42 (5). Further studies are ongoing to evaluate
the efficacy and safety of FcRn blockade in the treatment of
pemphigus.
Pemphigoid
Dr. Karen Harman (University of Nottingham, Nottingham, UK)
explained the characteristics of pragmatic and non-inferiority
trials, illustrated by the BLISTER (bullous pemphigoid steroids
and tetracyclines) study (ISRCTN13704604). A pragmatic trial is
designed to reflect everyday clinical practice and represents the
opposite end of the spectrum to an explanatory trial, performed
under ideal conditions. The degree of pragmatism is measured
over 9 domains using the PRECIS-2 tool. A non-inferiority
trial is used to assess whether a test treatment is not clinically
worse than standard care (control) by more than an acceptable
predetermined margin (the non-inferiority margin) and comes
from the concept of an acceptable alternative that may not be
quite as effective standard care but may have other advantages
such as cost, convenience or side-effects. The BLISTER study
concluded that doxycycline is non-inferior to oral prednisolone
for short-term disease control in bullous pemphigoid and
significantly safer in the long-term (6).
Since bullous pemphigoid is characterized by a predominance
of eosinophils both in the skin and in the blood, it is logical
to target the eosinophil by treating with an antibody directed
against eotaxin, a chemokine whose levels are elevated in the
skin and blood of patients with BP. Dr. Neil Korman (Case
Western Reserve University, Cleveland, OH, USA) discussed the
results of a pilot phase 2a study of the safety and efficacy of
bertilimumab, an anti-eotaxin-1 antibody, in the treatment of
patients with bullous pemphigoid (NCT02226146). The results
demonstrated that bertilimumab was safe and efficacious in the
treatment of bullous pemphigoid. Despite only receiving three
bertilimumab infusions and low doses of prednisone that were
rapidly tapered, the nine subjects in this study showed rapid and
durable improvement in disease activity with an 81% reduction
in disease severity, along with a significant steroid-sparing effect.
These promising preliminary findings should be followed up with
larger controlled trial of longer duration.
Dr. Janet Fairley (University of Iowa, Iowa City, IA, USA)
reviewed the current state of therapeutic clinical trials in
bullous pemphigoid and studies of the mechanisms of lesion
formation that could lead to new treatments. Currently there
are no approved drugs for pemphigoid, and the advanced
age of these patients and their co-morbidities have made
clinical trials challenging. However, recently a number of
new treatment options have been identified. Potential targets
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include complement, eosinophil chemotaxis and activation,
polymorphonuclear cells, IgE and IgE receptors, IgG turnover,
and cytokines. Several of these therapeutic strategies have
shown promise in pre-clinical trials and case reports or case
series. Larger controlled trials may lead to better treatments for
pemphigoid patients.
CLINICAL TRIAL ENROLLMENT AND
OUTCOMES
The second session of the meeting discussed data using disease-
specific instruments that may help to determine clinical trial
enrollment and outcomes, moderated by Drs. Katerina Patsatsi
(Aristotle University School of Medicine, Thessaloniki, Greece)
and Michael Hertl (Philipps-Universität Marburg, Marburg,
Germany).
Dr. Jun Yamagami (Keio University, Tokyo, Japan) discussed
a longitudinal study to quantify disease extent throughout the
course of pemphigus and pemphigoid therapy, in order to better
understand how the change in PDAI (Pemphigus Disease Area
Index) or BPDAI (Bullous Pemphigoid Disease Area Index)
score within the first 2 weeks from the initial treatment predicts
whether the patient will require additional treatment. The
study found significant change in the PDAI/BPDAI scores from
baseline to 2 weeks between patients who needed additional
treatment and those who did not, indicating that the ratio of
PDAI/BPDAI scores could be useful as an objective parameter to
determine the necessity of additional treatments.
Dr. Victoria Werth (University of Pennsylvania, Philadelphia,
USA) discussed assessing the “quality” of quality of life surveys
in autoimmune blistering disease. There are currently a number
of skin-specific and one disease-specific autoimmune blistering
disease quality of life instruments. A meta-analysis of health
related quality of life in pemphigus identified at least 16 quality
of life studies using 8 different instruments. It is important
to determine which of the main instruments used capture
the impact of disease on patients for both epidemiologic and
therapeutic studies. This study sought to compare the change in
three quality of life measures, including the autoimmune bullous
diseases quality of life (ABQOL) questionnaire, the Dermatology
Life Quality Index (DLQI), and the Skindex-29 (the latter of
which has three subscores for symptoms, function, and emotion),
with change in disease severity (measured in pemphigus with
the Pemphigus Disease Area Index (PDAI) and Autoimmune
Bullous Skin Disorder Intensity Score (ABSIS), and in bullous
pemphigoid with the Bullous Pemphigoid Disease Area Index
(BPDAI) and ABSIS) (7). Twenty three patients with mucosal
involvement and 27 without mucosal involvement were enrolled
and followed prospectively for a mean of 4.6 months. Sixty eight
percent had pemphigus vulgaris, 12% had pemphigus foliaceus,
and 20% had bullous pemphigoid. The Skindex-29 symptoms
subscore correlated best with the change in disease severity
(r = 0.75) relative to the ABQOL and DLQI (r = 0.65 and
0.68). The ABQOL had the best correlation with change in
mucosal disease severity relative to Skindex-29 symptoms and
DLQI (r = 0.77 vs. 0.66 and 0.56), and the Skindex-29 symptoms
relative to ABQOL and DLQI had the best correlation with
change in skin disease severity (r = 0.81 vs. 0.0.59 and 0.75).
Overall the change in BPDAI and PDAI correlated more strongly
with quality of life measurements than the ABSIS. Dr. Werth
noted that the patients enrolled in the study had relatively mild
disease, and higher correlations with the PDAI and BPDAI may
reflect the ability to capture low disease activity accurately with
these instruments.
PATIENT REPORTED OUTCOMES
The third session of the meeting focused on patient-reported
outcomes, moderated by Drs. Meng Pan (Shanghai Jiao Tong
University, Shanghai, China) and Animesh Sinha (University at
Buffalo, Buffalo, NY, USA).
On behalf of the International Pemphigus and Pemphigoid
Foundation (IPPF), Marc Yale (IPPF, Sacramento, CA, USA)
summarized the Natural History Study being conducted by
the IPPF. The IPPF Natural History Study is a new patient
registry sponsored by the National Organization for Rare
Disorders (NORD) and the US Food and Drug Administration
(FDA). This online data system collects, stores, and retrieves
patient data for analysis in research studies (https://pemphigus.
iamrare.org/). The IPPF Natural History Study serves to
provide a convenient online platform for patients or their
legally authorized representative to report cases of pemphigus
and pemphigoid, conduct a prospectively-planned natural
history study that will result in the most comprehensive
understanding of both diseases and their progression over time,
and characterize and describe the pemphigus and pemphigoid
population as a whole. In addition, it also serves to assist the
pemphigus and pemphigoid community with the development
of recommendations for standards of care, assist researchers
studying the pathophysiology of pemphigus and pemphigoid,
and support the design of clinical trials that explore new
pemphigus and pemphigoid treatments. The IPPF Natural
History Study is designed to help the medical and research
community understand illness trends, treatment outcomes,
disease burden, and some important demographic information
about patient age and gender. With this vital information from
large numbers of pemphigus and pemphigoid patients, the IPPF
can better advocate for resources to improve patient support,
education and outreach, as well as accelerate research.
Subsequently, Odette Miller (pemphigus patient, New Jersey,
USA), Jeff Weisgerber (pemphigus patient, North Carolina,
USA), Dr. Diana Chen (Genentech, South San Francisco, CA,
USA), Ann Neale (Principia Biopharma, South San Francisco,
CA, USA), and Dr. Donna Culton (University of North Carolina,
Chapel Hill, NC, USA) led a panel discussion to allow patients
who have participated in recent trials, as well as pharmaceuticals
and investigators who have enrolled advanced phase clinical trials
in pemphigus and pemphigoid to share their experiences.
COLLABORATIVE NETWORKS FOR RARE
DISEASE RESEARCH
The co-founder of the CastlemanDisease Collaborative Network,
Dr. David Fajgenbaum (University of Pennsylvania, Philadelphia,
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PA, USA) gave a keynote speech on the “collaborative network
approach” that has helped to spearhead to accelerate research
and drug discovery for Castleman disease (8). This information is
significant because Castleman disease is one of the most common
causes of paraneoplastic pemphigus, a highly deadly form of
pemphigus. As rare diseases share many of the same hurdles
in the way of drug discovery, there are great opportunities to
leverage aspects of the collaborative network approach to make
progress for pemphigus and other rare diseases.
CLINICAL TRIALS OF NOVEL CELLULAR
THERAPIES FOR PEMPHIGUS
The fifth session of the meeting focused on future clinical trials
in pemphigus, moderated by Drs. Annette Czernik (Icahn School
of Medicine at Mount Sinai, New York, NY, USA) and Donna
Culton (University of North Carolina, Chapel Hill, NC, USA).
In the pathogenesis of pemphigus, loss of immune tolerance to
themajor autoantigen desmoglein (Dsg) 3 is the key event leading
to the production of Dsg-reactive autoantibodies. Dr. Rüdiger
Eming (Philipps-Universität Marburg, Marburg, Germany)
described strategies to restore immune tolerance to Dsg3 in
the CD4+ T cell compartment by applying an HLA-transgenic
mouse model of pemphigus. The study has shown that injecting
animals with a set of immunodominant HLA-DRß1∗04:02-
binding Dsg3 peptides that are linked either to cellular
carriers (splenocytes) or to defined particles (nanoparticles)
prevents the induction of Dsg3-specific IgG antibodies upon
Dsg3 immunization. Moreover, T cell reactivity to Dsg3
in vitro is markedly reduced in mice that previously received
immunodominant Dsg3 peptides under tolerizing conditions.
These results in the preclinical model provide the rationale for the
development of a future phase I/II clinical trial to restore immune
tolerance to Dsg3 in pemphigus vulgaris (PV) patients.
Adapted from a groundbreaking gene-engineered chimeric
antigen receptor (CAR) T cell therapy that has led to long-
lasting remissions of previously refractory B cell leukemia
and lymphoma, Dsg3 chimeric autoantibody receptor T cell
(DSG3-CAART) therapy has been shown to induce histologic
and serologic remission of experimental pemphigus without
detectable off-target toxicity in preclinical mouse models (9).
Dr. Aimee Payne (University of Pennsylvania, Philadelphia, PA,
USA) discussed strategies to move CAART technology forward
to clinical trials in both mucosal PV, caused by antibodies to
Dsg3, and inmucocutaneous PV, characterized by autoantibodies
to Dsg3 and the homologous protein Dsg1. Dr. Payne reported
that DSG1-CAART alone, and combined DSG1- and DSG3-
CAART cells showed specific cytolysis of anti-DSG B cells, and
no detectable toxicity to human skin xenografts in vivo. A first-
in-human phase 1 clinical trial of DSG3-CAART in PV is planned
to evaluate its safety and therapeutic potential.
Dr. Haley Naik (University of California San Francisco, San
Francisco, CA, USA) reported on an autologous polyclonal
regulatory T cell therapy as a strategy for limiting autoantibody
production by augmenting immune regulation and re-
establishing immune tolerance. A phase 1 open-label multicenter
trial of autologous polyclonal regulatory T cells in patients with
active pemphigus vulgaris and pemphigus foliaceus is being
conducted toward this end (NCT03239470). In addition to
clinical evaluation for safety, this study also aims to assess the
presence and persistence of transferred regulatory T cells in
blood and skin, alterations in the tissue immunologic milieu, and
disease-specific and immunologic biomarkers in blood and skin.
Safety and efficacy data generated from this study will lay the
foundation for future studies using antigen-specific regulatory T
cell therapy.
EMERGING THERAPIES IN CLINICAL
DEVELOPMENT FOR PEMPHIGOID
The final invited speaker session covered future clinical trials
in pemphigoid, moderated by Drs. Peter Marinkovich Stanford
University, Stanford, CA, USA) and Soo-Chan Kim (Yonsei
University, Seoul, Korea).
Dr. Marcel Jonkman (University of Groningen, Groningen,
Netherlands) summarized an international survey on unmet
needs in pemphigoid diseases to explore and prioritize unmet
needs from the perspectives of patients, clinicians, and
researchers. The priority need for patients is a quicker diagnosis,
for clinicians labeling of new drugs, and for researchers more
head-to-head randomized controlled trials. All surveyed groups
agreed on a high need for improvement of current treatment
options, and future research should focus on this unmet need.
Dr. Ralf Ludwig (University of Lübeck, Lübeck, Germany)
reported on an upcoming clinical trial evaluating the safety and
efficacy of dimethyl fumarate (DMF) in bullous pemphigoid,
which will enroll the first patients this year in France, Germany,
Poland and Turkey (DPemTrial). This trial was based on findings
in preclinical animal models of epidermolysis bullosa acquisita
(EBA) (10), where DMF reduced clinical disease severity in mice
with already clinically manifest skin lesions. In addition to DMF,
preclinical EBAmodels (11) have defined several new therapeutic
targets, i.e., SYK (12, 13) and novel compounds (14).
Dr. Christian Sadik (University of Lübeck, Lübeck, Germany)
presented the topic of the C5a-LTB4 axis in bullous pemphigoid
diseases (15). The eicosanoid leukotriene B4 (LTB4) and the
complement factor C5, the precursor of the anaphylatoxin
C5a, are both abundant in lesional skin of bullous pemphigoid
patients, but their significance for the pathogenesis of bullous
pemphigoid or other pemphigoid diseases is still largely elusive.
In his talk, Dr. Christian Sadik demonstrated preclinical results
from mouse models of pemphigoid diseases pointing at a critical
role of LTB4 in the recruitment of granulocytes to the dermal-
epidermal junction (16). He discussed evidence that LTB4 may
closely interact with C5a in the regulation of skin inflammation
and that hence, inhibiting these two factors individually or in
parallel may be effective in the treatment of pemphigoid diseases.
CONCLUSIONS
The next decade offers exciting promise for an increasing number
of clinical trials in pemphigus and pemphigoid as new preclinical
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programs advance to clinic and existing clinical stage companies
apply their technologies to the treatment of pemphigus and
pemphigoid. The patients, physicians, and researchers in the
pemphigus and pemphigoid community remain committed to
advocating for treatment options that improve the health and
quality of life for pemphigus and pemphigoid patients.
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